Posts Tagged ‘Genome Key’
GenomeKey raise Innovate UK funding to drive life-saving next-gen sepsis diagnostic
Our member GenomeKey, has secured an Innovate UK Biomedical Catalyst research award of £950,000 towards faster diagnosis and treatment of sepsis, one of the world’s most deadly diseases. The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, save money,…
Read MoreCARB-X is funding UK-biotech GenomeKey to develop a rapid diagnostic for sepsis, a leading cause of death in hospitals
(BOSTON) – CARB-X is awarding SETsquared Bristol member, GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $9.5 million in grant funding to develop an innovative rapid diagnostic for sepsis. The new diagnostic would significantly reduce the time it takes to determine what bacteria are causing an infection and which antibiotics would be most effective…
Read MoreGenomeKey raises investment from Bristol Private Equity Club
A group of Bristol-based entrepreneurs has invested £192k into SETsquared Bristol member, GenomeKey, a research and development startup which is searching for faster diagnosis and treatment of sepsis. Sixteen members of Bristol Private Equity Club (BPEC) have backed GenomeKey, which is carrying out the pioneering research programme in Bristol. The investment will enable GenomeKey to leverage…
Read More